# RenalSense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renalsense

- Industry: Medical Devices & Equipment
- Headquarters: Jerusalem, Israel
- Website: www.renalsense.com
- Total disclosed funding: $14M
- Latest round: Series A (Nov 22, 2021)
- Investors on record: 1

## About

RenalSense Ltd is a medical technology company focused on enhancing kidney health management through innovative monitoring solutions that facilitate real-time tracking of kidney function for healthcare professionals.RenalSense Ltd, founded in 2010 and headquartered in Jerusalem, Israel, specializes in developing advanced monitoring solutions for kidney health. The company has engaged in a single investment deal, raising USD 14.00 mn in Series A funding on November 22, 2021, led by BlueRed Partners. CEO Avi Kleiman leads the firm, focusing on improving renal care through its innovative products.RenalSense specializes in advanced medical technology designed to enhance kidney health management through innovative monitoring solutions. The company’s core offerings include proprietary devices that enable real-time monitoring of kidney function, allowing healthcare professionals to make informed decisions regarding patient care. These products target hospitals, nephrologists, and healthcare providers treating patients with chronic kidney disease and those at risk of acute kidney injury. RenalSense’s solutions seamlessly integrate into existing healthcare systems, improving patient outcomes and reducing hospital readmission rates while being marketed primarily in North America and Europe.RenalSense generates revenue through direct sales and subscription-based models tailored for healthcare institutions. The company engages in B2B transactions, where hospitals and clinics purchase its monitoring devices, complemented by ongoing software subscriptions providing data analytics and support services. This structure ensures continuous access to updates and enhancements, maximizing client value from RenalSense products. Flagship products significantly contribute to revenue, often bundled with comprehensive training and support services, fostering long-term relationships with clients in the healthcare sector.In November 2021, RenalSense Ltd raised USD 14.00 mn in Series A funding to strengthen its distribution network and expand its product line. The company is focused on designing and launching new products to enhance its offerings and is exploring expansion into new markets. Specific target markets for expansion have not been disclosed, but the funding will support these initiatives to broaden the reach of its innovative kidney health solutions.

## Funding rounds

- Series A, Nov 22, 2021, $14M — BlueRed Partners

## Investors

- BlueRed Partners (https://capitalatlas.ai/funds/bluered-partners) — Series A